371 – 380 of 526
- show: 10
- |
- sort: year (new to old)
Close
Embed this list
<iframe src=" "
width=" "
height=" "
allowtransparency="true"
frameborder="0">
</iframe>
- 2016
-
Mark
Increased amyloidogenic APP processing in APOE ɛ4-negative individuals with cerebral β-amyloidosis.
(
- Contribution to journal › Article
-
Mark
Longitudinal Measurements of Cerebrospinal Fluid Biomarkers in Parkinson's Disease.
2016) In Movement Disorders(
- Contribution to journal › Article
-
Mark
Cerebral white matter lesions - associations with Aβ isoforms and amyloid PET.
(
- Contribution to journal › Article
-
Mark
18F-AV-1451 tau PET imaging correlates strongly with tau neuropathology in MAPT mutation carriers
(
- Contribution to journal › Article
-
Mark
Preclinical amyloid-β and axonal degeneration pathology in delirium
(
- Contribution to journal › Article
-
Mark
Reference measurement procedure for CSF amyloid beta (Aβ)1–42 and the CSF Aβ1–42/Aβ1–40 ratio – a cross-validation study against amyloid PET
(
- Contribution to journal › Article
-
Mark
The pre-synaptic vesicle protein synaptotagmin is a novel biomarker for Alzheimer's disease
(
- Contribution to journal › Article
-
Mark
Reply : Do we still need positron emission tomography for early Alzheimer's disease diagnosis?
(
- Contribution to journal › Letter
-
Mark
Assessing risk for preclinical β-amyloid pathology with APOE, cognitive, and demographic information
(
- Contribution to journal › Article
-
Mark
Cerebrospinal fluid tau, neurogranin, and neurofilament light in Alzheimer's disease
(
- Contribution to journal › Article